28.35 USD
▲+0.39+9.42%
盘后 26.29 +1.48%
2026-08-03
市值
$2.82B
市盈率
—
EPS
-0.64
股息率
—
52 周区间
15.60 – 38.26
成交量
2.15M
Beta
2.18
目标价
52.31
52W 低 15.6052W 高 38.26
价格走势
公司简介
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk...